1. Scrip

WHO looks at how better to respond to a pandemic

 
• By Ian Schofield

The World Health Organization is to hold a workshop in October to discuss the lessons learned from the handling of the flu pandemic and how to respond more effectively to such events in future. Topics will include the need for better co-ordination among countries, the purchasing and use of vaccines and antivirals, and the role of the pharmaceutical industry.

The World Health Organization is to hold a workshop in October to discuss the lessons learned from the handling of the flu pandemic and how to respond more effectively to such events in future. Topics will include the need for better co-ordination among countries, the purchasing and use of vaccines and antivirals, and the role of the pharmaceutical industry.

The workshop will be based on the results of an ongoing evaluation of countries' pandemic responses that is being conducted...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.